All articles by Phillip Broadwith – Page 12
-
Opinion
Taking responsibility seriously
Companies have a duty to be proactive when it comes to sustainability
-
BusinessAn unsustainable hypocrisy
Social responsibility should extend through the whole supply chain, not just be a tool to put pressure on feedstock suppliers
-
Business
Celgene backs immunotherapy with Juno collaboration
$1bn investment in 10-year CAR-T cell partnership for cancer treatments
-
Business
Thermo Fisher to buy Alfa Aesar chemical supplies
Research chemicals business no longer a strategic fit for owner Johnson Matthey
-
Business
Blast kills six at South Korean chemical plant
One further worker injured as tank explodes during welding work
-
Business
Job cuts at Allergan and Transgene
Allergan is shedding 300 staff at former Actavis site in Iceland, while Transgene is closing its French manufacturing plant with loss of 120 jobs
-
Business
Fracking prohibited in New York state and Lancashire
Local US and UK rulings prohibit shale oil drilling and exploration
-
ResearchCollaboration, not competition
Organic chemist E J Corey talks to Phillip Broadwith about awards, ambition and academic freedom
-
Business
Vertex nabs rights to cystic fibrosis molecules
Deal with Parion, worth up to $1bn, gives firm worldwide rights to investigational treatments that complement Vertex’s existing cystic fibrosis drugs
-
Business
Opko deepens diagnostics with $1.5bn lab buyout
Taking over clinical diagnostics service provider BioReference Laboratories gives Opko a bigger avenue to distribute and market its diagnostic tests
-
Business
Takeda to consolidate vaccines business in Boston
Firm will close three recently-acquired US sites and shift operations to the growing pharmaceutical hub in Massachusetts
-
Business
OM Group to be sold and split
Apollo Global Management will buy the firm for $1bn, then sell electronic materials business to Platform Specialty Products
-
Business
Teva fined $1.2bn in pay-for-delay case
Company illegally blocked generic competition of sleep disorder drug, and settlement terms tighten up rules on anticompetitive behaviour
-
Business
Achillion partners with Janssen to boost hepatitis C pipeline
Development deal worth up to $1.1bn includes three investigational drugs aiming to extend treatment options in fast-moving market
-
Business
Actavis plan to thwart generics blocked
Company prevented from withdrawing original formulation of Alzheimer’s drug to force patients onto extended release version and extend patent exclusivity
-
Business
Endo to buy Par as generics consolidation continues
$8bn deal follows trend as drugmakers aim for economies of scale
-
Business
GSK commits to HIV research
Firm will partner with US university and cancels plan to sell its share of ViiV Healthcare joint venture
-
Business
DuPont overcomes investor challenge
Shareholders decline to elect activist board nominees in a show of support for the current management’s strategy